Abstract: The present invention provides a novel alizarin derivative compound and a simplified and low cost method for preparing an alizarin derivative compound including: obtaining a compound represented by Formula (2) using a compound represented by Formula (3); and obtaining an alizarin derivative compound represented by Formula (1) using the compound represented by Formula (2); in Formulae (1) to (3), R1 represents a hydrogen atom or a substituent; n represents an integer of 1 to 3, L represents a specific alkyl group; Q represents an atomic group needed to form an aromatic ring or a heteroaromatic ring with adjacent carbon atoms; and P represents an atomic group which includes an atom(s) selected from a hydrogen atom, a carbon atom, an oxygen atom, a sulfur atom, a silicon atom and a boron atom, and which is needed to form a ring structure group with adjacent two oxygen atoms and two carbon atoms;

Abstract: An embodiment of the present disclosure can include a compound, a structure bonded to the compound, and the like. In an embodiment, the compound can be a linker between an agent and a structure, where the agent can be a dye or a pigment and the structure can be a fiber, hair, or another structure. In an embodiment, the compound can be a linker between an agent and a structure, where the agent can be a fluorinated compound and the structure can be a counter top, metal, or the like.

Abstract: Use of chemical ingredients in Cynomorium as phytoestrogen is provided by the present invention. Particularly, use of Cynomorium, extracts of Cynomorium, or at least one ingredient chosen from chrysophanol, emodin, catechin, (?)-epicatechin-3-O-gallate, naringenin-4?-O-glucopyranoside, and phlorizin, in manufacturing medicaments for treating and/or preventing diseases related to insufficient of estrogen secretion in mammal (for example, human), or use in manufacturing medicaments used as phytoestrogens is provided by the present invention. The extracts of Cynomorium, compositions containing extracts of Cynomorium or active ingredients thereof, and methods of treating and/or preventing diseases related to insufficient of estrogen secretion are also provided by the present invention.

Abstract: The present invention provides a novel alizarin derivative compound and a simplified and low cost method for preparing an alizarin derivative compound including: obtaining a compound represented by Formula (2) using a compound represented by Formula (3); and obtaining an alizarin derivative compound represented by Formula (1) using the compound represented by Formula (2); in Formulae (1) to (3), R1 represents a hydrogen atom or a substituent; n represents an integer of 1 to 3, L represents a specific alkyl group; Q represents an atomic group needed to form an aromatic ring or a heteroaromatic ring with adjacent carbon atoms; and P represents an atomic group which includes an atom(s) selected from a hydrogen atom, a carbon atom, an oxygen atom, a sulfur atom, a silicon atom and a boron atom, and which is needed to form a ring structure group with adjacent two oxygen atoms and two carbon atoms;

Abstract: The invention relates to two novel substances, namely (1R,2S,3S,4R)-3-acetoxy-1,2,4,5-tetrahydroxy-7-methoxy-2-methyl-1,2,3,4-tetrahydroanthracene-9,10-dione (3-O-acetyl altersolanol M) and 8-(4,5,6-trihydroxy-7-methyl-2-methoxy-9,10-dioxo-9H,10H-anthracen-1-yl)-(1S,2S,3R,4S)-1,2,3,4,5-pentahydroxy-7-methoxy-2-methyl-1,2,3,4-tetrahydro-9H,10H-anthracene-9,10-dione (the atropisomers alterporriol I and J) to their use as anti-infectives and as anti-cancer agents, as well as to methods of producing the same.

Abstract: Compositions derived from Rheum palmatum are provided. Also provided are methods of using said extracts to induce apoptosis in specific cells, especially in a human.

Abstract: The subject of the present invention is the use, for dyeing in particular human keratin materials, of a specific direct anthraquinone dye by dry thermal transfer. Its subject is furthermore a method for dyeing keratin materials, in which at least one direct anthraquinone dye contained in a dry composition is applied to or close to the keratin materials, and a source of heat is applied, causing the thermal transfer of the direct dye(s) at the surface and/or inside the keratin materials. It relates furthermore to the dry composition and a method for preparing it.

Abstract: Anthraquinones are described which are antihelminthic and in particular, are useful in compositions for inhibiting Schistosoma sp. in vitro or in vivo. The preferred anthraquinones have the formula: wherein R1, R2, R3, and R4 are each hydrogen, hydroxy, halogen, alkyl, substituted alkyl, alkene, substituted alkene, alkyne, aryl, substituted aryl, cyclic, substituted cyclic, acid group, carbohydrate, or combination thereof, R is a group containing 1 to 12 carbons such as methyl, alkyl, substituted alkyl, aldehyde, hydroxy, hydroxymethyl, acid group, carbohydrate, or combination thereof, and the halogen is I, F, Br, or Cl.

Abstract: Anthraquinones are described which are antihelminthic and in particular, are useful in compositions for inhibiting Schistosoma sp. in vitro or in vivo. The preferred anthraquinones have the formula: wherein R1, R2, R3, and R4 are each hydrogen, hydroxy, halogen, alkyl, substituted alkyl, alkene, substituted alkene, alkyne, aryl, substituted aryl, cyclic, substituted cyclic, acid group, carbohydrate, or combination thereof, R is a group containing 1 to 12 carbons such as methyl, alkyl, substituted alkyl, aldehyde, hydroxy, hydroxymethyl, acid group, carbohydrate, or combination thereof, and the halogen is I, F, Br, or Cl.

Abstract: Anthraquinones are described which have anticancer or antitumor activity and which are useful for inhibiting cancer cells and cells comprising tumors in vitro or in vivo. Preferably, the anthraquinones have the chemical formula: wherein R1 is selected from the group consisting of hydrogen, alkyl, and substituted alkyl; R2 is a group containing 1-12 carbons selected from the group consisting of alkyl, substituted alkyl, aldehyde, hydroxy, hydroxymethyl, acid group, carbohydrate and combinations thereof; and R3 is a group containing 1 to 12 carbons selected from the group consisting of methyl, alkyl, substituted alkyl, aldehyde, hydroxy, hydroxymethyl, acid group, carbohydrate, and combinations thereof.

Abstract: Anthraquinones are described which are antihelminthic and in particular, are useful in compositions for inhibiting Schistosoma sp. in vitro or in vivo. The preferred anthraquinones have the formula: wherein R1, R2, R3, and R4 are each hydrogen, hydroxy, halogen, alkyl, substituted alkyl, alkene, substituted alkene, alkyne, aryl, substituted aryl, cyclic, substituted cyclic, acid group, carbohydrate, or combination thereof, R is a group containing 1 to 12 carbons such as methyl, alkyl, substituted alkyl, aldehyde, hydroxy, hydroxymethyl, acid group, carbohydrate, or combination thereof, and the halogen is I, F, Br, or Cl.

Abstract: Anthraquinones are described which are antihelminthic and in particular, are useful in compositions for inhibiting Schistosoma sp. in vitro or in vivo. The preferred anthraquinones have the formula: wherein R1, R2, R3, and R4 are each hydrogen, hydroxy, halogen, alkyl, substituted alkyl, alkene, substituted alkene, alkyne, aryl, substituted aryl, cyclic, substituted cyclic, acid group, carbohydrate, or combination thereof, R is a group containing 1 to 12 carbons such as methyl, alkyl, substituted alkyl, aldehyde, hydroxy, hydroxymethyl, acid group, carbohydrate, or combination thereof, and the halogen is I, F, Br, or Cl.

Abstract: A novel compound with anthraquinone structure and having the following foluma (I): wherein R1, R2 and R3 each independently is hydrogen, hydroxy, amino or C1-6 alkyl group; R4 is hydrogen, C1-18 alkyl carbonyl, C1-6 alkyl group substituted by at least a functional group; R5 is hydrogen amino or a group of the following formula wherein R1, R2, R3 and R4 are defined as the above; and R and R′ each independently is hydrogen, hydroxyl, amino, C1-6 alkyl group or a group of the following formula wherein R1, R2, R3 and R4 are defined as the above.

Abstract: Disclosed are novel colorant compounds which contain one or more ethylenically-unsaturated (vinyl), photopolymerizable radicals which may be copolymewrized (or cured) with ethylenically-unsaturated monomers to produce colored compositions such as colored acrylic coatings and polymers, e.g., coatings and polymers produced from acrylate and methacrylate esters, colored polystyrenes, and similar colored polymeric materials derived from other ethylenically-unsaturated monomers. The present invention also pertains to processes for the preparation of certain of the photopolymerizable colorant compounds.

Abstract: A thermal cutoff member and compositions used to manufacture such members are described herein as including at least two organic compounds which, when sufficiently combined, give rise to a component which has a lower melt transition temperature than the initial organic compounds prior to combining the same. The thermal cutoff member is generally utilized in a thermal cutoff construction having an electrical switching unit that changes its operating condition when the member therein melts by being heated to a certain temperature for the particular material that forms the member being utilized.

Abstract: Solid phases of (−)-cis-FTC, which are designated herein as amorphous (−)-FTC and Forms II and III (−)-cis-FTC) are provided that can be distinguished from Form I (−)-cis-FTC by X-ray powder diffraction patterns, thermal properties, and methods of manufacture. A hydrated crystalline form of (±)-cis-FTC (i.e. racemic cis-FTC), and a dehydrated form of the hydrate, are also provided, and can similarly be distinguished from other forms of FTC by X-ray powder diffraction patterns, thermal properties, and methods of manufacture. These FTC forms can be used in the manufacture of other forms of FTC, or in pharmaceutical compositions. Particularly preferred uses of these forms are in the treatment of HIV or hepatitis B.

Abstract: The invention relates to novel soluble pigment precursors possessing not only higher thermal stability but also improved solubility characteristics and to a process for mass coloration of high temperature polymers that utilizes these novel soluble pigment precursors.

Abstract: A pharmaceutical composition for treating a hepatic disorder, comprising a triterpene derivative represented by the formula (I) or a pharmaceutically acceptable salt thereof is disclosed: wherein R1 represents a hydroxyl group, alkoxy, alkylcarbonyloxy, or aralkyloxy; R2 represents alkyl, —CH2OR5, wherein R5 represents a hydrogen atom, alkyl, aralkyl, or alkylcarbonyl, formyl, —COOR6, wherein R6 represents a hydrogen atom or alkyl, or —CH2N(R7)R8; or R1 and R2 combine with each other to form —O—CR9(R10)—OCH2—, wherein R9 and R10, which may be the same or different, represent a hydrogen atom, alkyl, or aryl; R3 and R4, which may be the same or different, represent a hydrogen atom, a hydroxyl group, alkyl, hydroxyalkyl, formyl, —COOR11, wherein R11 represents a hydrogen atom or alkyl, or —OR12, wherein R12 represents alkyl, aralkyl, C1-6 alkylcarbonyl, arylcarbonyl, alkenyl, alkenylcarbonyl, or arylalkenylcarbonyl which may be optionally s

Abstract: The present invention discloses a tertiary non-linear optical material comprising a quinone derivative expressed by any one of the general formulas: ##STR1## wherein R.sup.1, R.sup.2, R.sup.3, R.sup.4, R.sup.5 and R.sup.6 are as defined above, or the formula: ##STR2## The tertiary non-linear material enables the co-existence of large tertiary non-linear optical susceptibility and high-speed response.

Abstract: A pharmaceutical compound of the formula ##STR1## in which R is hydrogen, halo or F.sub.2 HCO--; or a salt, amide or ester thereof, useful in the treatment of skeletal diseases.

Abstract: Pharmaceutical compounds of the formula ##STR1## in which R.sup.1 and R.sup.2 are each hydrogen, hydroxyl, halo, C.sub.1-4 alkyl, C.sub.1-4 alkoxy, acyloxy, --O-glucoside, optionally substituted phenyl or optionally substituted phenyl-C.sub.1-4 alkoxy;R.sup.3 istetrazolyl, orand R.sup.4 and R.sup.5 are each hydrogen, hydroxy, acyloxy, nitro, C.sub.1-4 alkyl, C.sub.1-4 alkoxy, halo, optionally substituted phenyl, --SO.sub.3 H or --NR'R" where R' and R" are each hydrogen or C.sub.1-4 alkyl;provided that when R.sup.3 is --CR'R".CHR'"CO.sub.2 H or tetrazolyl, R.sup.1 and R.sup.2 are each hydroxyl, halo, C.sub.1-4 alkyl, C.sub.1-4 alkoxy, acyloxy, --O-glucoside, optionally substituted phenyl or optionally substituted phenyl C.sub.1-4 alkoxy; andor a pharmaceutically acceptable salt or ester thereof.

Abstract: The invention relates to the synthesis of 6-deoxykermesates, 6-deoxykermesic acid, and carminic acid, based on a reaction of a 2-halogenonapthazarin with a bis-trimethylsilyl-diene.

Abstract: The present invention relates to intermediates, pradimic acids and pradimic acid amides of the formula (II) ##STR1## wherein R is OH or NH.sub.2 ; R.sup.1 is hydrogen or a group of the formula ##STR2## with the proviso that when R is OH, R.sup.1 is not hydrogen; Y is OH or NR.sup.2 R.sup.3 ; R.sup.2 is hydrogen or methyl; R.sup.3 is hydrogen, C.sub.1-5 alkyl, or an amino protecting group; R.sup.4 is hydrogen, hydroxy protecting group, or .beta.-D-xylosyl. The invention relates also to novel processes for the preparation of pradimic acids and pradimic acid amides, as well as novel pradimicin derivatives prepared therefrom.

Abstract: An industrially useful process for the production of an aromatic hydroxy compound which comprises reacting an aromatic sulfonic acid alkali metal salt and/or an aromatic sulfonic acid with an alkali metal hydroxide in the presence of a surface active agent, wherein the reaction is effected by uniformly dispersing these-materials in a reaction medium selected from aliphatic, alicyclic and aromatic hydrocarbons. By employing this process, the product can be obtained with high purity, high yield and high selectivity using a minimum amount of the alkali metal hydroxide.

Abstract: This invention provides novel anti-tumour compounds of the formula ##STR1## wherein R.sub.1 and R.sub.2 are hydrogen or together form an alkyl-, alkoxy- or OH-substituted aromatic group, which optionally contains an N atom as a hetero-atom; R is --COCH.sub.3 or --C.tbd.C--R.sub.4 and R.sub.4 is H or trimethylsilyl; and R.sub.3 is H or --COCF.sub.3 ; and acid addition salts thereof; as well as compositions containing these compounds.

Abstract: The invention provides novel cyclic triketone compounds of the formulae ##STR1## wherein S is H, alkyl or alkoxy and R* is a group of the formule ##STR2## wherein R.sup.1 is methyl and R.sub.2 is an alkyl group containing at least 2 carbon atoms or R.sup.1 is an alkyl group having 1-4 carbon atoms and R.sup.2 is an aryl group, a hetero aryl group, a --CH.sub.2 OR' group, a --CH.sub.2 N< group, a --CH.sub.2 SR" group or a --CH.sub.2 CH.dbd.CH.sub.2 group, wherein R' and R" are alkyl groups having 1-4 carbon atoms.These compounds can be used for preparing daunomycinone and derivatives thereof. Daunomycinone is used for preparing daunomycin and adriamycin.by introducing chirality at C-1 of ring A in the preparation of said novel compounds by using a novel diene of formula (1) in a Diels-Alder reaction for said preparation, the chirality of C-3 is established in the subsequent reaction with LiC.tbd.CSi(CH.sub.3).sub.3 in the synthesis of daunomycinone and derivatives thereof.

Abstract: A method for causing laxation using 1, 3, 6, 8-tetrahydroxyanthraquinone.